Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 51Urinary Bladder Neoplasms 15Breast Neoplasms 10Carcinoma, Renal Cell 8Colorectal Neoplasms 7Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Non-Small-Cell Lung 4Motor Activity 3Colonic Neoplasms 3Urologic Neoplasms 2Urologic Diseases 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Rectal Neoplasms 2Prostate Cancer Metastatic 2Neoplasms by Site 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Kidney Failure, Chronic 2Esophageal Neoplasms 2COVID-19 2Breast Neoplasms, Male 2

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2Standard of Care 2Cystectomy 2B701 protein, Human herpesvirus 6 2valrubicin 1trifluridine tipiracil drug combination 1testosterone 17 beta-cypionate 1palbociclib 1enfortumab vedotin 1atezolizumab 1Water 1Valsartan 1Urinary Diversion 1Tranexamic Acid 1Therapeutics 1Testosterone Propionate 1Sunitinib 1Stents 1Radiosurgery 1Radiation Dose Hypofractionation 1Practice Guidelines as Topic 1Nephrotomy 1Nephrostomy, Percutaneous 1Methyltestosterone 1Immune Checkpoint Inhibitors 1Ice 1Hydroxychloroquine 1Health Information Exchange 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urologic Diseases × Standard of Care × Genitourinary × Clear all
NCT04731376 2026-05-26

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Emory University

Phase 1 Active not recruiting
56 enrolled
Genitourinary

Hypogonadism, Urologic Diseases, Urologic Neoplasms

NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡